<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30176834</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>31</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1471-2407</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>18</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>03</Day>                    </PubDate>                </JournalIssue>                <Title>BMC cancer</Title>                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>864</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-018-4778-7</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Anthracycline chemotherapy agents are commonly used to treat breast cancer, but also result in cardiac injury, and potentially detrimental effects to vascular and skeletal muscle. Preclinical evidence demonstrates that exercise and caloric restriction can independently reduce anthracycline-related injury to the heart as well as cancer progression, and may be promising short-term strategies prior to treatment administration. For women with breast cancer, a short-term strategy may be more feasible and appealing, as maintaining regular exercise training or a diet throughout chemotherapy can be challenging due to treatment symptoms and psychosocial distress.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">The Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study will determine whether acute application of these interventions shortly prior to receipt of each treatment can reduce anthracycline-related toxicity to the heart, aorta, and skeletal muscle. Fifty-six women with early stage breast cancer scheduled to receive anthracycline treatment will be randomly assigned to one of three groups who will: 1) perform a single, 30-min, vigorous-intensity, aerobic exercise session 24 h prior to each anthracycline treatment; 2) consume a prepared diet reduced to 50% of caloric needs for 48 h prior to each anthracycline treatment; or 3) receive usual cancer care. The primary outcome is magnetic resonance imaging (MRI) derived left ventricular ejection fraction reserve (peak exercise LVEF - resting LVEF) at the end of anthracycline treatment. Secondary outcomes include MRI-derived measures of cardiac, aortic and skeletal muscle structure and function, circulating NT-proBNP, cardiorespiratory fitness and treatment symptoms. Exploratory outcomes include quality of life, fatigue, tumor size (only in neoadjuvant patients), oxidative stress and antioxidants, as well as clinical cardiac or cancer outcomes. MRI, exercise tests, and questionnaires will be administered before, 2-3 weeks after the last anthracycline treatment, and one-year follow-up.</AbstractText>                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The proposed lifestyle interventions are accessible, low cost, drug-free potential methods for mitigating anthracycline-related toxicity. Reduced toxic effects on the heart, aorta and muscle are very likely to translate to short and long-term cardiovascular health benefits, including enhanced resilience to the effects of subsequent cancer treatment (e.g., radiation, trastuzumab) aging, and infection.</AbstractText>                <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT03131024; 4/21/18.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kirkham</LastName>                    <ForeName>Amy A</ForeName>                    <Initials>AA</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3847-1225</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering, University of Alberta, 1098 Research Transition Facility, 8308-114 Street, Edmonton, AB, T6G 2V2, Canada. amy.kirkham@ualberta.ca.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paterson</LastName>                    <ForeName>D Ian</ForeName>                    <Initials>DI</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine, Division of Cardiology, University of Alberta, Edmonton, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Prado</LastName>                    <ForeName>Carla M</ForeName>                    <Initials>CM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Agricultural, Food &amp; Nutrition Science, University of Alberta, Edmonton, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mackey</LastName>                    <ForeName>John M</ForeName>                    <Initials>JM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, University of Alberta, Edmonton, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Courneya</LastName>                    <ForeName>Kerry S</ForeName>                    <Initials>KS</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pituskin</LastName>                    <ForeName>Edith</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Faculty of Nursing, University of Alberta, Edmonton, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thompson</LastName>                    <ForeName>Richard B</ForeName>                    <Initials>RB</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering, University of Alberta, 1098 Research Transition Facility, 8308-114 Street, Edmonton, AB, T6G 2V2, Canada.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <DataBankList CompleteYN="Y">                <DataBank>                    <DataBankName>ClinicalTrials.gov</DataBankName>                    <AccessionNumberList>                        <AccessionNumber>NCT03131024</AccessionNumber>                    </AccessionNumberList>                </DataBank>            </DataBankList>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>PDF17483149</GrantID>                    <Agency>Susan G. Komen</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>03</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMC Cancer</MedlineTA>            <NlmUniqueID>100967800</NlmUniqueID>            <ISSNLinking>1471-2407</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018943">Anthracyclines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P188ANX8CK</RegistryNumber>                <NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Toxicol Appl Pharmacol. 2007 Nov 15;225(1):90-101</RefSource>                <PMID Version="1">17904602</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Diet Assoc. 2002 Nov;102(11):1621-30</RefSource>                <PMID Version="1">12449285</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2018 Feb;167(3):719-729</RefSource>                <PMID Version="1">29110150</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Aging Cell. 2010 Jun;9(3):304-12</RefSource>                <PMID Version="1">20121721</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Circ Cardiovasc Imaging. 2013 Mar 1;6(2):329-38</RefSource>                <PMID Version="1">23258478</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2016 Oct 4;11(10):e0163513</RefSource>                <PMID Version="1">27701422</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Brain Behav Immun. 2013 Mar;30 Suppl:S75-87</RefSource>                <PMID Version="1">22610066</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pain Symptom Manage. 2002 Dec;24(6):547-61</RefSource>                <PMID Version="1">12551804</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2000 Apr;36 Suppl 1:S11-4</RefSource>                <PMID Version="1">10785604</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Drugs. 1997;54 Suppl 4:1-7</RefSource>                <PMID Version="1">9361955</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2011 Nov 22;105(11):1663-8</RefSource>                <PMID Version="1">22068815</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cardiol. 2013 Sep 1;167(5):2306-10</RefSource>                <PMID Version="1">22727976</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Cycle. 2010 Nov 15;9(22):4474-6</RefSource>                <PMID Version="1">21088487</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cardiovasc Magn Reson. 2000;2(4):271-8</RefSource>                <PMID Version="1">11545126</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Clin Nutr. 2010 Jan;91(1):106-14</RefSource>                <PMID Version="1">19889820</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Obes Relat Metab Disord. 2001 Jul;25(7):929-34</RefSource>                <PMID Version="1">11443488</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2007 Sep 1;25(25):3808-15</RefSource>                <PMID Version="1">17664460</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Magn Reson Med. 2014 Jun;71(6):2082-95</RefSource>                <PMID Version="1">23881866</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Coll Cardiol. 1997 Dec;30(7):1758-64</RefSource>                <PMID Version="1">9385904</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World J Biol Chem. 2014 Aug 26;5(3):269-74</RefSource>                <PMID Version="1">25225594</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2010 Jun 29;10:337</RefSource>                <PMID Version="1">20587042</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2015 Mar 16;107(5):null</RefSource>                <PMID Version="1">25780062</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Sci (Lond). 2011 Jan;120(1):37-49</RefSource>                <PMID Version="1">20666733</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pain Symptom Manage. 2003 Nov;26(5):975-89</RefSource>                <PMID Version="1">14585549</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Physiol Biochem. 2013 Jun;69(2):177-87</RefSource>                <PMID Version="1">22890792</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 Jul 10;30(20):2530-7</RefSource>                <PMID Version="1">22614980</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Oral Sci. 2010 Mar;52(1):133-6</RefSource>                <PMID Version="1">20339244</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Clin Pathol. 2008 Nov;130(5):688-95</RefSource>                <PMID Version="1">18854260</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2015 Oct 05;15:652</RefSource>                <PMID Version="1">26438237</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2017 Aug;164(3):537-555</RefSource>                <PMID Version="1">28503723</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Oncol. 2015;2015:917606</RefSource>                <PMID Version="1">26339243</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8215-20</RefSource>                <PMID Version="1">18378900</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Coll Cardiol. 2012 Oct 16;60(16):1455-69</RefSource>                <PMID Version="1">22999723</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Circulation. 2015 Jun 2;131(22):1981-8</RefSource>                <PMID Version="1">25948538</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Carcinogenesis. 2010 Jan;31(1):83-9</RefSource>                <PMID Version="1">19969554</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cardiol. 2006 Jul 28;111(1):120-6</RefSource>                <PMID Version="1">16242796</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Asia Pac J Clin Oncol. 2013 Jun;9(2):155-61</RefSource>                <PMID Version="1">22897825</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Magn Reson Med. 2004 Jul;52(1):141-6</RefSource>                <PMID Version="1">15236377</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacol Rev. 2004 Jun;56(2):185-229</RefSource>                <PMID Version="1">15169927</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Heart Fail Clin. 2011 Jul;7(3):333-44</RefSource>                <PMID Version="1">21749885</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Appl Physiol (1985). 2009 Dec;107(6):1935-42</RefSource>                <PMID Version="1">19779154</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cardiovasc Res. 2012 Dec 1;96(3):456-65</RefSource>                <PMID Version="1">22952253</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Soc Echocardiogr. 2014 Sep;27(9):911-39</RefSource>                <PMID Version="1">25172399</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Soc Hypertens. 2010 Jan-Feb;4(1):7-13</RefSource>                <PMID Version="1">20374946</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Hematol. 2010 Nov;85(11):894-6</RefSource>                <PMID Version="1">20872550</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer J. 2005 Nov-Dec;11(6):449-60</RefSource>                <PMID Version="1">16393479</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2012 Mar;23(3):604-10</RefSource>                <PMID Version="1">21586686</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Coll Cardiol. 2006 Dec 5;48(11):2258-62</RefSource>                <PMID Version="1">17161256</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nutr Biochem. 2006 Aug;17(8):501-8</RefSource>                <PMID Version="1">16517142</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68</RefSource>                <PMID Version="1">24703918</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 Dec 20;30(36):4458-61</RefSource>                <PMID Version="1">23045598</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Integr Cancer Ther. 2008 Sep;7(3):147-54</RefSource>                <PMID Version="1">18815146</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2008 Mar 10;26(8):1201-3</RefSource>                <PMID Version="1">18227525</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cardiol. 2017 Oct 15;245:263-270</RefSource>                <PMID Version="1">28735755</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Womens Health. 2015 Jan 23;7:127-40</RefSource>                <PMID Version="1">25657599</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Sci Sports Exerc. 2018 Feb;50(2):177-186</RefSource>                <PMID Version="1">28991038</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Magn Reson Med. 2010 Jan;63(1):79-90</RefSource>                <PMID Version="1">19859956</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018943" MajorTopicYN="N">Anthracyclines</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D031204" MajorTopicYN="Y">Caloric Restriction</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D066126" MajorTopicYN="N">Cardiotoxicity</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005081" MajorTopicYN="Y">Exercise Therapy</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Anthracyclines</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Caloric restriction</Keyword>            <Keyword MajorTopicYN="N">Cardiotoxicity</Keyword>            <Keyword MajorTopicYN="N">Exercise</Keyword>            <Keyword MajorTopicYN="N">Magnetic resonance imaging</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30176834</ArticleId>            <ArticleId IdType="doi">10.1186/s12885-018-4778-7</ArticleId>            <ArticleId IdType="pii">10.1186/s12885-018-4778-7</ArticleId>            <ArticleId IdType="pmc">PMC6122558</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>